Etonogestrel Subdermal Implant in Adolescents: Everything We Should Know to Conduct Proper Counseling, a Narrative Review
Abstract
:1. Introduction
- -
- Copper IUD: a non-hormonal device that prevents pregnancy by creating an environment toxic to sperm;
- -
- Hormonal IUD: releases progestin (levonorgestrel) to thicken cervical mucus, inhibit sperm movement, and alter the uterine lining;
- -
- Contraceptive implants: a small rod placed under the skin of the upper arm that releases progestin to prevent ovulation and thicken cervical mucus.
2. Materials and Methods
- P (Population): adolescent individuals considering or using the etonogestrel subdermal implant;
- I (Intervention): counseling regarding the use and management of the implant;
- O (Outcome): improved understanding, informed decision making, and optimized implant use.
- Inclusion and Exclusion Criteria
- -
- Studies focusing on adolescents (10–19 years) considering or using the etonogestrel subdermal implant;
- -
- Reports addressing counseling regarding the implant, its use, and its outcomes;
- -
- Data on improved understanding, informed decision making, and optimized use of the implant.
- -
- Studies involving the wrong population (e.g., non-adolescents);
- -
- Reports not within the scope of the research focus;
- -
- Studies not reporting outcomes of interest or lacking specified adolescent data;
- -
- Reports focusing on abortion methods unrelated to the ENG implant.
- Grouping for Syntheses
- -
- The outcomes related to contraceptive use and counseling effectiveness;
- -
- Factors affecting adoption, retention, or discontinuation of the ENG implant.
- Sources Searched
- -
- Databases: PubMed, Embase, and CINAHL;
- -
- Other Sources: reference lists of relevant articles;
- -
- No time limits were applied to the search for inclusivity;
- -
- Last Search Date: January 2025.
- -
- Population: adolescents considering or using the ENG implant;
- -
- Intervention: counseling and implant use;
- -
- Outcome: understanding, decision making, and implant usage optimization.
- Study Screening and Data Collection
- -
- Screening: duplicate records (450) and irrelevant studies (120) were excluded before screening 2330 records. The process led to the inclusion of 17 studies;
- -
- Reviewers: the document does not specify the number of reviewers or whether the process was independent. This should be clarified in the final report;
- -
- Automation Tools: none applicable.
- Outcome and Variable Collection
- -
- Adherence to ENG implant use;
- -
- Counseling effectiveness and impact on contraceptive choices;
- -
- Adverse effects such as abnormal uterine bleeding or systemic effects.
- -
- Participant demographics (age, BMI, etc.);
- -
- Intervention characteristics (timing, counseling method, etc.);
- -
- Clinical outcomes (implant retention, side effects, etc.).
- Risk of Bias Assessment
- Effect Measures and Data Synthesis
- -
- Clinical efficacy rates (Pearl Index), continuation rates, and satisfaction levels;
- -
- Impact on adverse effects and contraceptive choice changes.
- -
- No meta-analysis or specific heterogeneity exploration mentioned. Results were synthesized narratively due to the nature of the study.
3. Results
3.1. Etonogestrel Subdermal Implant for Contraception: Mechanism of Action
3.1.1. Etonogestrel Subdermal Implant: Lights and Shadows
3.1.2. Abnormal Uterine Bleeding (AUB)
3.1.3. Body Weight and Body Max Index (BMI)
3.1.4. Incorrect Insertion, Breakage, and Bending of the Implant
3.1.5. Pregnancy During the Use of ENG Implants
3.1.6. Postpartum Contraception
3.1.7. Pain During Contraceptive Implant Insertion
3.1.8. Systemic Hormonal Effects
3.1.9. Comorbid Chronic Conditions
4. Discussion and Implication for Practice
- General Interpretation of the Results in the Context of the Living Literature
- -
- ENG implants are shown to improve adherence and satisfaction among adolescents compared to other contraceptive methods, consistent with recommendations by ACOG and WHO;
- -
- The barriers identified (e.g., abnormal uterine bleeding, fear of insertion) corroborate the existing literature, reinforcing the importance of tailored counseling and support to address such concerns;
- -
- The integration of LARCs into adolescent healthcare services aligns with global public health goals, such as the UN’s 2030 Agenda for Sustainable Development.
- Population-Specific Gaps:
- -
- Limited studies focused exclusively on adolescents;
- -
- Insufficient subgroup analyses for diverse demographics (e.g., cultural or socioeconomic variations, chronic conditions, etc.).
- Outcome Measurement:
- -
- Inconsistent reporting of outcomes like satisfaction, adherence, and long-term side effects;
- -
- Few studies examined psychosocial impacts, such as decision-making autonomy and parental influence.
- Geographic Bias:
- -
- Most studies were conducted in high-income countries, potentially limiting generalizability to low- and middle-income settings where healthcare access and cultural norms may differ.
- Search Strategy:
- -
- Although broad, the search strategy may have excluded non-English literature or unpublished studies, introducing potential language or publication bias.
- Study Selection and Screening:
- -
- The document does not detail whether multiple reviewers independently screened studies or resolved disagreements through consensus, which might introduce selection bias.
- Risk of Bias Assessment:
- -
- No explicit tools or frameworks were used to evaluate the methodological quality of included studies, potentially undermining the robustness of the findings.
- Synthesis Approach:
- -
- The narrative synthesis lacked quantitative integration, such as meta-analysis, limiting the ability to assess statistical heterogeneity or pooled effect sizes.
- For Practice:
- -
- Tailored, evidence-based counseling addressing common barriers (e.g., abnormal uterine bleeding) should be integrated into routine care for adolescents;
- -
- Providers should receive adequate training to deliver unbiased and comprehensive contraceptive advice;
- -
- Strategies to ensure equitable access, such as cost subsidies and confidential services, are essential to overcoming financial and social barriers.
- For Policy:
- -
- Policies prioritizing the inclusion of LARCs in adolescent health programs can help meet public health goals, such as reducing unintended pregnancies and unsafe abortions;
- -
- Programs targeting underserved regions or vulnerable populations should ensure culturally sensitive and accessible contraceptive services;
- -
- Governments and stakeholders should address financial barriers by subsidizing LARCs or incorporating them into universal health coverage schemes.
- For Future Research:
- -
- Conduct large-scale, prospective studies focusing on adolescents from diverse backgrounds to validate findings across different contexts;
- -
- Explore the psychosocial dimensions of LARC use, such as decision-making autonomy, stigma, and family involvement;
- -
- Investigate the long-term safety and efficacy of ENG implants, particularly in adolescents with chronic health conditions or obesity;
- -
- Develop and evaluate innovative counseling tools, including digital or visual aids, to enhance understanding and decision making among adolescents.
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Nexplanon_pi.pdf [Internet]. Available online: https://www.organon.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf (accessed on 11 August 2024).
- Meirik, O.; Fraser, I.S.; d’Arcangues, C. Implantable contraceptives for women. Hum. Reprod. Update 2003, 9, 49–59. [Google Scholar] [CrossRef] [PubMed]
- Nexplanon (Etonogestrel)—68 mg Subcutaneous Implant: Update of Insertion and Removal Instructions to Minimize the Risks of Neurovascular Damage and Implant Migration. Available online: http://www.hpra.ie/docs/default-source/default-document-library/important-safety-information---implanon-nxt-etonogestrel-68-mg-implant-for-subdermal-use.pdf?sfvrsn=0 (accessed on 9 December 2024).
- Moray, K.V.; Chaurasia, H.; Sachin, O.; Joshi, B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod. Health 2021, 18, 4. [Google Scholar] [CrossRef]
- Group BMJP. FSRH Guideline (February 2021) Progestogen-only Implant. BMJ Sex. Reprod. Health 2021, 47 (Suppl. S1), 1–62. [Google Scholar] [CrossRef] [PubMed]
- Levine, J.P.; Mleczko, J.A. Etonogestrel Subdermal Contraceptive Implant: Insertion and Removal. In Primary Care Procedures in Women’s Health: An International Guide for the Primary Care Setting (Internet); Heath, C., Sulik, S.M., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 175–198. [Google Scholar] [CrossRef]
- Green, S.; Sheeder, J.; Richards, M. The Etonogestrel Implant in Adolescents: Factors Associated With Removal for Bothersome Bleeding in the First Year After Insertion. J. Pediatr. Adolesc. Gynecol. 2021, 34, 825–831. [Google Scholar] [CrossRef] [PubMed]
- McNicholas, C.; Swor, E.; Wan, L.; Peipert, J.F. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am. J. Obstet. Gynecol. 2017, 216, 586.e1–586.e6. [Google Scholar] [CrossRef]
- Lewis, L.N.; Doherty, D.A.; Hickey, M.; Skinner, S.R. Implanon as a contraceptive choice for teenage mothers: A comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010, 81, 421–426. [Google Scholar] [CrossRef]
- Milliren, C.E.; DiVasta, A.D.; Edwards, A.J.; Maslyanskaya, S.; Borzutzky, C.; Pitts, S. Contraceptive Implant-Associated Bleeding in Adolescent/Young Adult Clinical Practice: Associated Factors, Management, and Rates of Discontinuation. J. Adolesc Health 2023, 72, 583–590. [Google Scholar] [CrossRef]
- Fei, Y.F.; Smith, Y.R.; Dendrinos, M.L.; Rosen, M.W.; Quint, E.H. Considerations in Adolescent Use of the Etonogestrel Subdermal Implant: A Cohort Study. Front. Reprod. Health 2021, 3, 780902. [Google Scholar] [CrossRef]
- Lazorwitz, A.; Aquilante, C.L.; Sheeder, J.; Guiahi, M.; Teal, S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100, 37–41. [Google Scholar] [CrossRef] [PubMed]
- Tyson, N.; Lopez, M.; Merchant, M.; Postlethwaite, D. Subdermal Contraceptive Implant Insertion Trends and Retention in Adolescents. J. Pediatr. Adolesc. Gynecol. 2021, 34, 348–354. [Google Scholar] [CrossRef] [PubMed]
- Pitts, S.; Milliren, C.E.; Borzutzky, C.; Maslyanskaya, S.; Berg, G.; DiVasta, A.D. Adolescent/Young Adult Long-Acting Reversible Contraception: Experience from a Multisite Adolescent Medicine Collaborative. J. Pediatr. 2022, 243, 158–166. [Google Scholar] [CrossRef]
- Obijuru, L.; Bumpus, S.; Auinger, P.; Baldwin, C.D. Etonogestrel Implants in Adolescents: Experience, Satisfaction, and Continuation. J. Adolesc. Health 2016, 58, 284–289. [Google Scholar] [CrossRef] [PubMed]
- Romano, M.E.; Braun-Courville, D.K. Assessing Weight Status in Adolescent and Young Adult Users of the Etonogestrel Contraceptive Implant. J. Pediatr. Adolesc. Gynecol. 2019, 32, 409–414. [Google Scholar] [CrossRef] [PubMed]
- Tsevat, D.; Mercier, R.; Bernheimer, C.; Lin, S.; Schwartz, B. Amenorrhea in adolescents using the etonogestrel contraceptive implant. Contraception 2024, 133, 110413. [Google Scholar] [CrossRef]
- Scott, N.; Silver, E.J.; Dodson, N.A.; Coupey, S.M. Does Obesity Influence Body Mass Index Changes in Nulliparous Adolescent Users of Long-Acting Reversible Contraceptives? J. Pediatr. Adolesc. Gynecol. 2021, 34, 815–820. [Google Scholar] [CrossRef] [PubMed]
- Batt, C.E.; Sheeder, J.; Love-Osborne, K. Weight Gain Patterns in Adolescent and Young Adult Women with the Etonogestrel Implant: Comparison by Weight Category. J. Adolesc. Health 2021, 69, 815–823. [Google Scholar] [CrossRef] [PubMed]
- Food and Drug Administration (FDA) Nexplanon Product Label (Internet). Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021529s011lbl.pdf (accessed on 9 December 2024).
- DailyMed—NEXPLANON—Impianto di Etonogestrel (Internet). Available online: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487f8a62-e142-457c-97cc-2e398fde7594 (accessed on 9 December 2024).
- United Nations Department of Economic and Social Affairs. World Family Planning 2020: Highlights: Accelerating Action to Ensure Universal Access to Family Planning (Internet). United Nations, 2020. Available online: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Sep/unpd_2020_worldfamilyplanning_highlights.pdf (accessed on 9 December 2024).
- Boos, M.D.; Ryan, M.E.; Milliren, C.; Golub, S.; Maslyanskaya, S.; Escovedo, M.; DiVasta, A.; Pitts, S. Relationship between long-acting reversible contraception and acne in a cohort of adolescents and young adults. Pediatr. Dermatol. 2024, 41, 628–634. [Google Scholar] [CrossRef]
- Long-Acting Reversible Contraception Implants and Intrauterine Devices (Internet). Available online: https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/11/long-acting-reversible-contraception-implants-and-intrauterine-devices (accessed on 9 December 2024).
- Buyers, E.; Sass, A.E.; Severn, C.D.; Pyle, L.; Cree-Green, M. Twelve-month Continuation of the Etonogestrel Implant in Adolescents with Polycystic Ovary Syndrome. J. Pediatr. Adolesc. Gynecol. 2021, 34, 33–39. [Google Scholar] [CrossRef]
- Giraudo, F.; Salinas, A.; Merino, P.M.; Iñiguez, G.; López, P.; Castro, A.; Lardone, M.C.; Cavada, G.; Cassorla, F.; Codner, E. Subdermal Progestin Implant and an Oral Combined Hormonal Contraceptive in Youth with Type 1 Diabetes. J. Pediatr. Adolesc. Gynecol. 2024, 37, 177–183. [Google Scholar] [CrossRef]
- Family Planning/Contraception Methods (Internet). Available online: https://www.who.int/news-room/fact-sheets/detail/family-planning-contraception (accessed on 9 August 2024).
- Bentsianov, S.D.; Brandi, K.; Chen, P.; Shimoni, N. A Pilot Study to Understand the Adolescent Pain Experience During Contraceptive Implant Insertion. J. Pediatr. Adolesc. Gynecol. 2021, 34, 522–524. [Google Scholar] [CrossRef]
- Callahan, D.G.; Garabedian, L.F.; Harney, K.F.; DiVasta, A.D. Will it Hurt? The Intrauterine Device Insertion Experience and Long-Term Acceptability Among Adolescents and Young Women. J. Pediatr. Adolesc. Gynecol. 2019, 32, 615–621. [Google Scholar] [CrossRef] [PubMed]
- Pritt, N.M.; Norris, A.H.; Berlan, E.D. Barriers and Facilitators to Adolescents’ Use of Long-Acting Reversible Contraceptives. J. Pediatr. Adolesc. Gynecol. 2017, 30, 18–22. [Google Scholar] [CrossRef]
- Secura, G.M.; Madden, T.; McNicholas, C.; Mullersman, J.; Buckel, C.M.; Zhao, Q.; Peipert, J.F. Provision of No-Cost, Long-Acting Contraception and Teenage Pregnancy. N. Engl. J. Med. 2014, 371, 1316–1323. [Google Scholar] [CrossRef] [PubMed]
- Eeckhaut, M.C.W.; Fitzpatrick, K. Are LARC Users Less Likely to Use Condoms? An Analysis of U.S. Women Initiating LARC in 2008–2018. Women’s Health Issues 2022, 32, 431–439. [Google Scholar] [CrossRef]
- Bachorik, A.; Friedman, J.; Fox, A.; Nucci, A.T.; Horowitz, C.R.; Diaz, A. Adolescent and young adult women’s knowledge of and attitudes toward etonogestrel implants. J. Pediatr. Adolesc. Gynecol. 2015, 28, 229–233. [Google Scholar] [CrossRef]
- Rosenthal, M.A.; McQuillan, S.K. Adolescent contraception. Can. Med. Assoc. J. 2021, 193, E1218. [Google Scholar] [CrossRef]
- Inthavong, S.; Pantasri, T.; Morakote, N.; Muangmool, T.; Piyamongkol, W.; Pongsatha, S.; Chaovisitseree, S. Change of contraceptive preference after the free-LARC program for Thai teenagers. BMC Women’s Health 2022, 22, 211. [Google Scholar] [CrossRef]
- Promoting Healthy Sexual Development and Sexual, CDC-Reproductive Healthity (Internet). Available online: https://publications.aap.org/pediatriccare/book/342/chapter-abstract/5742873/Promoting-Healthy-Sexual-Development-and-Sexuality?redirectedFrom=fulltext (accessed on 9 December 2024).
- Hansen, R.T.B.; Arora, K.S. Consenting to invasive contraceptives: An ethical analysis of adolescent decision-making authority for long-acting reversible contraception. J. Med. Ethics 2018, 44, 585–588. [Google Scholar] [CrossRef]
- Cohen, R.; Sheeder, J.; Kane, M.; Teal, S.B. Factors Associated With Contraceptive Method Choice and Initiation in Adolescents and Young Women. J. Adolesc. Health 2017, 61, 454–460. [Google Scholar] [CrossRef]
- Berlan, E.; Valenti, O.; Long, W.; Toth, C.; Abenaim, A.; Maciejewski, H.; Gowda, C. Practice Facilitation Improves Adolescent Reproductive Health Preventive Services in Primary Care. Pediatrics 2022, 149, e2020035774. [Google Scholar] [CrossRef] [PubMed]
- Vayngortin, T.; Bachrach, L.; Patel, S.; Tebb, K. Adolescents’ Acceptance of Long-Acting Reversible Contraception After an Educational Intervention in the Emergency Department: A Randomized Controlled Trial. West. J. Emerg. Med. 2020, 21, 640–646. [Google Scholar] [CrossRef] [PubMed]
- Santibenchakul, S.; Thanativakul, K.; Jaisamrarn, U. An educational video on long-acting reversible contraception as a counseling tool for postpartum adolescents. Contracept. Reprod. Med. 2022, 7, 24. [Google Scholar] [CrossRef]
- Harris, K.; Byrd, K.; Engel, M.; Weeks, K.; Ahlers-Schmidt, C.R. Internet-Based Information on Long-Acting Reversible Contraception for Adolescents. J. Prim. Care Community Health 2016, 7, 76–80. [Google Scholar] [CrossRef]
- Rinehart, D.J.; Leslie, S.; Durfee, M.J.; Stowell, M.; Cox-Martin, M.; Thomas-Gale, T.; Shlay, J.C.; Havranek, E.P. Acceptability and Efficacy of a Sexual Health Texting Intervention Designed to Support Adolescent Females. Acad. Pediatr. 2020, 20, 475–484. [Google Scholar] [CrossRef]
- Barney, A.; Rodriguez, F.; Schwarz, E.B.; Reed, R.; Tancredi, D.; Brindis, C.D.; Dehlendorf, C.; Tebb, T.P. Adapting to Changes in Teen Pregnancy Prevention Research: Social Media as an Expedited Recruitment Strategy. J. Adolesc. Health 2021, 69, 349–353. [Google Scholar] [CrossRef] [PubMed]
- Hubacher, D. Long-acting reversible contraception acceptability and satisfaction is high among adolescents. BMJ Evid-Based Med. 2017, 22, 228–229. [Google Scholar] [CrossRef] [PubMed]
- Bornstein, M.; Carter, M.; Zapata, L.; Gavin, L.; Moskosky, S. Access to long-acting reversible contraception among US publicly funded health centers. Contraception 2018, 97, 405–410. [Google Scholar] [CrossRef]
- Berlan, E.D.; Richards, M.J.; Vieira, C.S.; Creinin, M.D.; Kaunitz, A.M.; Fraser, I.S.; Edelman, A.; Mansour, D. Best Practices for Counseling Adolescents about the Etonogestrel Implant. J. Pediatr. Adolesc. Gynecol. 2020, 33, 448–454. [Google Scholar] [CrossRef] [PubMed]
- Kavanaugh, M.L.; Pliskin, E.; Hussain, R. Associations Between Unfulfilled Contraceptive Preferences Due to Cost and Low-Income Patients’ Access to and Experiences of Contraceptive Care in the United States, 2015–2019; Contracept X (Internet); Kavanaugh, M.L., Pliskin, E., Hussain, R., Eds.; Guttmacher Institute: New York, NY, USA, 2022; Volume 4. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
Barriers to the Use of ENG Implants Among Adolescents |
---|
|
|
|
|
|
|
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Messina, A.; Elmotarajji, S.; Dalmasso, E.; Valentini, C.; Remorgida, V.; Leo, L.; Libretti, A.; Masturzo, B. Etonogestrel Subdermal Implant in Adolescents: Everything We Should Know to Conduct Proper Counseling, a Narrative Review. Clin. Pract. 2025, 15, 27. https://doi.org/10.3390/clinpract15020027
Messina A, Elmotarajji S, Dalmasso E, Valentini C, Remorgida V, Leo L, Libretti A, Masturzo B. Etonogestrel Subdermal Implant in Adolescents: Everything We Should Know to Conduct Proper Counseling, a Narrative Review. Clinics and Practice. 2025; 15(2):27. https://doi.org/10.3390/clinpract15020027
Chicago/Turabian StyleMessina, Alessandro, Safae Elmotarajji, Eleonora Dalmasso, Costanza Valentini, Valentino Remorgida, Livio Leo, Alessandro Libretti, and Bianca Masturzo. 2025. "Etonogestrel Subdermal Implant in Adolescents: Everything We Should Know to Conduct Proper Counseling, a Narrative Review" Clinics and Practice 15, no. 2: 27. https://doi.org/10.3390/clinpract15020027
APA StyleMessina, A., Elmotarajji, S., Dalmasso, E., Valentini, C., Remorgida, V., Leo, L., Libretti, A., & Masturzo, B. (2025). Etonogestrel Subdermal Implant in Adolescents: Everything We Should Know to Conduct Proper Counseling, a Narrative Review. Clinics and Practice, 15(2), 27. https://doi.org/10.3390/clinpract15020027